M - HERBALNET Digital Repository

tenderness at the end of the second and fourth week were 0.69 * 0.3 and 0.46 0.3 1 respectively
that were significantly less @ < 0.05) than 1.09 * 0.33, the mean baseline score for joint
tenderness (Figure 2).
Comparison of pre (NSAIDs supplemented with MI&) and post treatment (Sallaki after
withdrawal of NSAIDs) values
When therapy with NSAlD was withdrawn and only Sallaki administered for a period of two
weeks from the fourth week of study period, no significant difference in the joint tenderness
score at the sixth as compared to the fourth week was observed. However the mean score for
joint tenderness at the end of the sixth week was 0.46 h 0.35 that was significantly less (p < 0.05)
than 1.09 * 0.33, the mean baseline score for joint pain (Figure 2).
Joint swelling
Comparison of pre flSAIDs therapy) and psi treatment (NSAIDs supplemented with ,%llakr}
values
Supplementing the existing NSAID therapy with Sallaki resulted in a significant reduction in the
swelling of the affected joints at the 2-w&k and 4-week endpoint. The mean score for joint
swelling at the end of the second and fourth week were 0.54 * 0.28 and 0.33 * 0.29 respectively
that were significantly less (p < 0.05) than 0.82 * 0.27, the mean baseline score for jbint swelling
(Figure 3)
Comparison of pre (IvSAIDs supplemented with SalU) and post treatment (Sallaki sfter
withdrawal of NWDs) values
When therapy with NSAID was withdrawn and only Sallaki administered for a period of two
weeks fiom the fourth week of study period, no significant difference in the joint swelling score
at the sixth as compared to the fourth week was observed. However the mean score for joint
swelling at the end of the sixth week was 0.34 * 0.33 that was significantly less @ < 0.05) than
0.82 * 0.27, the mean baseline score for joint swelling (Figure 3).
Morning stiffn~s
Comparison of pre (1VUIDs therapyl and post treatment (NLUIDs supplemented with SallakI)
values
Supplementing the existing NSAID therapy with Sallaki resulted in a yignificant reduction in
mcrning' stiffness of the affected joints at the 2-week and 4-week endpoint. The mean score for
morning stiffness at the end of the second and fourth week were 0.7 0.34 and 0.47 0.3
respectively that were significantly less @ < 0.05) than 1.05 * 0.46, the mean baseline score for
morning stiffness pigure 4).
Comparison of pre (NSAIDs supplemented with Sallaki) and post treatment (Salk& after
withdrawal of NWDs) values
When therapy with NSAlD was withdrawn and only Sallaki administered for a period of ,two
weeks &om the fourth week of study period, no significant diffwence in the morning stiffness
score at the sixth as compared to the fourth week was observed. However the mean ocore.for
morning stiffness at the end of the sixth week wab 0.45 * 0.37 that was significantly less @ <
0.05) than 1.05 * 0.46, the mean baseline score for morning stiffness (Figure 4).
SELECT RESEARCH PAPERS ON EVIDENCE BASED AYURVEDIC DRUGS 144
-